Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
This study will assess further the safety and tolerability of long-term treatment with
 omalizumab by extending omalizumab treatment by 1 year for those patients with allergic
 asthma who successfully completed study CIGE25011E2.
Inclusion Criteria:

 -  Patients with a history of severe allergic asthma who completed the treatment period
 of CIGE250011E3 protocol, without experiencing any significant drug-related adverse
 events

 -  Male or female patients 12-75 years of age who have given written informed consent
 approved by the ethical committee

 Exclusion Criteria:

 -  Patients who had not received study medication for greater than 84 days since visit 38
 of study CIGE240011E3

 -  Pregnant females or nursing mothers

 -  Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs

 Other protocol-defined inclusion/exclusion criteria may apply